Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Fisher & Paykel Healthcare (ASX:FPH) share price soars on HY23 result

The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price is up 12% after revealing its HY23 result and outlining some FY23 commentary.

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is up 12% after revealing its HY23 result and outlining some FY23 commentary.

Fisher & Paykel Healthcare says it’s a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.

HY23 result

Here are some of the main highlights from the result for the six months to 30 September 2022:

  • Operating revenue of $690.6 million was down 23%, though this beat the $670 million guidance
  • Net profit after tax (NPAT) was $95.9 million, or a 57% decline from the prior comparable period
  • Increased interim dividend by around 3% to 17.5 cents per share

The company explained that its numbers were down because it was lapping against significant COVID-19-driven demand. But, compared to pre-COVID times, this represented “solid growth”. Compared to the first half of FY20, revenue was up 21%.

Revenue breakdown

In the hospital product group, which includes humidification products used in respiratory, acute and surgical care, revenue was $438.7 million. That was a 35% year on year decline, though it was up 24% compared to the first half of FY20.

Management said that there were positive signs that its hospital customers are working through excess inventory. Hospital consumables have increased sequentially on a month by month basis since May. This trend “has continued in the second half to date.” This is another positive sign for the Fisher & Paykel Healthcare share price.

In the homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, revenue rose by 10% to $249.9 million. OSA masks and accessories revenue increased 16%.

Management said that there had been a strong reception of its new Evora full mask where it began selling into the US in April after approval.

Gross profit margin reduces

The company reported that its gross profit margin was 59.8%, down from 63.1% in the prior period and below the company’s long-term target of 65%. Although global freight rates are seeing prices soften, legs in and out of New Zealand are lagging this trend, which continues to weigh on the margin.

Fisher & Paykel Healthcare has also been impacted by “manufacturing inefficiencies”.

Outlook for the Fisher & Paykel Healthcare share price

The second half of FY23 is expected to see higher revenue than the first half.

It’s expecting this within its hospital product group, with seasonal patterns resulting in higher sales of hospital consumables in the second half. It is also likely that some customers will have worked through their COVID-driven consumables stock.

In the homecare product group, it believes that the recent launch of the new Evora full face mask, combined with improving global supply of CPAP hardware, will contribute to continued growth for the remainder of the year.

It’s also expecting the second half gross profit margin would improve compared to the first half by approximately 200 basis points.

With the Fisher & Paykel Healthcare share price down 30% this year, it could be an opportunity, though it’s not one I have on my own watchlist.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content